Skip to content


BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma

  • Jie Chen2,
  • Meng Fang1,
  • Xiaoling Chen3,
  • Changhong Yi1,
  • Jun Ji1,
  • Cheng Cheng1,
  • Mengmeng Wang1,
  • Xing Gu1,
  • Quansheng Sun1 and
  • Chunfang Gao1Email author
Contributed equally
BMC Cancer201717:881

Received: 16 January 2017

Accepted: 8 December 2017

Published: 21 December 2017



Because glycosylation is one of the most common post-translational modifications of proteins and because changes in glycosylation have been shown to have a significant correlation with the development of many cancer types, we investigated the serum N-glycome used to diagnose, stage and evaluate the pathological outcomes in IgD multiple myeloma.


Serum samples were available for 20 patients with IgD multiple myeloma, 41 patients with light chain multiple myeloma and 42 healthy control subjects. Serum N-glycans were released and analysed using DNA sequencer-assisted fluorophore-assisted capillary electrophoresis.


Characteristic changes were revealed in the serum N-glycome of IgD myeloma. In particular, three N-glycans (NG1(6)A2F, Peak3; NG1(3)A2F, Peak4; NA2FB, Peak7) showed increased clinical value. The best area under the ROC curve of NG1(6)A2F to diagnose IgD myeloma was 0.981, with a 95.0% sensitivity and 95.2% specificity, and that of NG1(3)A2F was 0.936, with a 95.0% sensitivity and 78.6% specificity. The best area under the ROC curve of NA2FB/NG1(3)A2F to differentially diagnose IgD myeloma versus light chain myeloma was 0.744, with a 95.3% sensitivity and 50.0% specificity. The level of NG1(3)A2F was correlated with the international staging system, while the higher abundance of NA2FB presented in IgD myeloma was predictive of a shorter progression-free survival.


The advent of serum N-glycan signatures may play a role in the diagnosis, staging and prognosis of IgD myeloma and will serve as the foundation for a precision medicine approach to this rare subtype of multiple myeloma.


IgD multiple myelomaN-glycan profilingGlycosylationBiomarkerDiagnosisPrognosis


Multiple myeloma (MM) is a B-cell malignancy characterized by the expansion of malignant plasma cells within the bone marrow. IgD multiple myeloma (IgD MM) is an uncommon variant of MM, accounting for approximately 1% to 2% of myeloma cases. IgD MM has been characterized by relatively younger patients, male predominance, extramedullary involvement, osteolytic lesions, a λ chain bias, Bence Jones proteinuria, renal dysfunction and a poor prognosis [14].

Glycosylation is the stepwise procedure of the covalent attachment of oligosaccharide chains to proteins or lipids that may influence biological activity, stability, pharmacokinetics, and antigenicity, among other activities [5]. Oligosaccharides may be present as N-linked or O-linked forms. Variations in N-linked oligosaccharides are involved in many pathological conditions such as chronic diseases and cancers [69]. Recently, Mittermayr S et al. [10] have demonstrates the feasibility of mapping glycan modifications on the IgG molecule and provided the principle that differential IgG glycosylation patterns can be successfully identified in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), active MM, complete-response post-treatment MM and relapse MM. Kovacs Z et al. [11] have indicated 12 N-glycan features showed statistically significant differences among various stages of MM in comparison to the control at the serum level, while only six features were identified with similar significance at the immunoglobulin level, including the analysis of the partitioned Fc fragment as well as the Fab κ and Fab λ chains. Consequently, the identification and reliable quantification of glycan biomarkers from serum samples may enable non-invasive cancer screening for diagnosis and prognosis. Over the past decade, the development of high-throughput N-glycan profiling methods (e.g. DNA sequencer-assisted fluorophore-assisted capillary electrophoresis, i.e., DSA-FACE) has enabled researchers to pursue the role of glycomics as potential disease biomarkers [12].

The findings related to the glycosylation of proteoglycan syndecan-1 (CD138) emphasize its relevance to growth, metastasis, prognosis and targeted therapy of MM. Syndecan-1 acts as a positive regulator of many effective molecules important for myeloma growth and survival, such as a proliferation-inducing ligand (APRIL), epidermal growth factor (EGF) family members, insulin-like growth factor (IGF), insulin-like growth factor binding proteins (IGFBP) or hepatocyte growth factor (HGF) and an inhibitor of human heparanase or heparinase III [1318]. Until now, little was known regarding the changes in N-glycans in IgD MM. We recently demonstrated that the serum N-glycan profile models distinguished patients with light chain multiple myeloma (LCMM) from healthy control subjects (CTRs) and differentiated LCMM from other subtypes of multiple myeloma (IgG and IgA) [19].

One distinctive feature of IgD MM is the smaller size or absence of the monoclonal protein spike [20], which leads to false-negative results by conventional techniques (e.g., serum protein electrophoresis [SPE] and immunofixation electrophoresis [IFE]). Pandey S [21] reported that the serum concentrations of IgG and IgA were 1020 mg/dL to 1460 mg/dL and 210 mg/dL to 350 mg/dL, respectively, much higher than the level of IgD in serum (0 to 10 mg/dL). Thus, the undetectability or low amount of serum IgD may cause diagnostic errors (e.g., osteoclasia or impaired renal function) and a delayed diagnosis (e.g., diagnosed first as LCMM or non-secretory MM). The purpose of this study was to examine the serum N-glycan levels in patients with IgD MM and identify whether N-glycans could serve as diagnostic and prognostic markers for this condition.


Patients and serum samples

Representative serum samples from MM patients recruited during a 2-year period (March 2010 to April 2012) at Shanghai Jingan District Zhabei Central Hospital were studied, excluding those with the IgG or IgA subtype. Additionally, serum samples from healthy donors who were deemed free of diseases after a physical examination were collected. The 61 MM patients consisted of 20 IgD MM patients and 41 LCMM patients, and 42 CTRs were evaluated. All MM patients were defined based on the International Myeloma Working Group (IMWG) criteria 2003 [Clonal bone marrow plasma cells ≥10%, presence of serum or urinary monoclonal protein (except in patients with true non-secretory MM), and evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder] and were staged according to the international staging system (ISS) and Durie–Salmon staging system after a confirmed diagnosis [22, 23]. Both newly diagnosed MM patients and confirmed MM patients who were undergoing routine chemotherapy were included in the study. MM patients who had serious infectious diseases, acute or chronic inflammatory diseases, history of another malignant cancer besides MM, and drug abuse were excluded. The serum samples from newly diagnosed and treated patients were obtained before chemotherapy initiation and before the next chemotherapy session, respectively. Based on a computerized database and medical records of all patients seen at the hospital, the progression-free survival (PFS) and overall survival (OS) of 20 patients with IgD MM were monitored. Blood was collected using a standard protocol and serum samples were separated by centrifugation at 3000 rpm for 10 min, followed by storage at −80 °C until analysis. Nine patients were newly diagnosed and 11 were already treated in the IgD MM group. All the patients were already symptomatic or became symptomatic during follow-up. Next, the symptomatic patients were treated with conventional modalities. The median follow-up for IgD MM patients was 31.5 months.

Laboratory tests and clinical features

The haematological index of the haemoglobin (Hb) level was determined using an automatic cell counter and associated reagent (Sysmex XZ-2100D Cell Counter; Sysmex, Kobe, Japan; Sysmex diagnostic reagents). Biochemical indexes, such as total protein (TP), albumin (ALB), urea (BUN) and creatinine (CREA) were measured using an automatic chemical analyser and associated reagent (ADVIA 2400 Analyzer; Siemens AG, Munich, Germany; Siemens diagnostic reagents). SPE and IFE were run using a semi-auto electrophoresis system (Sebia HYDRASYS2 electrophoresis system; Sebia, Tours, France). Serum and urine light chain levels were analysed on a Dade Behring BNII nephelometer (Siemens AG; Siemens diagnostic reagents).

Clinical features, such as bone lesion and extramedullary infiltration were documented from the medical records of patients with IgD MM.

PFS was calculated from the start of the first treatment to disease progression or death from any cause, or the date on which the patient was last known to be in remission. OS was calculated from the start of first treatment to the date of death or the date on which the patient was last known to be alive. For the analysis of the correlation between N-glycan abundance and survival, PFS or OS, the patients were divided into two groups: one group had a specific N-glycan structure level less than the median level, and the other group had a specific N-glycan structure level above the median level.

Serum protein N-glycan profiling

The N-glycans present on the serum proteins were analysed using DSA-FACE technology as described previously [12, 24]. Briefly, the N-linked glycans were denatured and released from serum glycoproteins by adding the peptide N-glycosidase-F (PNGaseF) (New England Biolabs, Boston, MA) in 2 μl of serum. Thereafter, N-glycans were labelled with APTS (8-aminonaphtalene-1, 3, 6-trisulphonic acid) (Invitrogen, Carlsbad, CA). Sialic acid was removed using Arthrobacter ureafaciens sialidase (Roche Bioscience, Palo Alto, CA) and the processed samples were analysed using a capillary electrophoresis-based ABI3500 Genetic Analyzer (Applied Biosystems, Foster city, CA). Twelve obvious N-glycan peaks detected in all serum samples were analysed using the GeneMapper v4.1 software (Applied Biosystems). The abundance of each N-glycan peak was described by normalizing its height to the sum of the heights of all 12 peaks. Before applying DSA-FACE method to discover N-glycan biomarkers for IgD myeloma, we have evaluated the feasibility of this method, such as test reproducibility. The coefficient of variation (CV) value of run-to-run was less than 15% for each N-glycan marker. In addition, a pooled serum was aliquoted as the standard sample, and it was analyzed in each experiment to ensure the stability of the system and the reliability of the results (Additional file 1: Table S1).

Statistical analysis

All quantitative variables are expressed as means ± standard deviation (SD). Quantitative variables were compared using Student’s t test, ANOVA or nonparametric tests. After one-way ANOVA, the LSD (least significance difference) test was applied for pair-wise comparison between the three groups. Pearson’s coefficients of correlation and their associated probabilities (P) were used to evaluate the relationship between the peak values and other independent parameters. The diagnostic or differentially diagnostic performance of a single marker was evaluated by receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated using cut-off values optimally selected based on the ROC curves. Survival curves were estimated according to the Kaplan-Meier method. Differences between survival curves were tested for statistical significance using the two-sided log-rank test. All reported P values were 2-tailed, and P values <0.05 were evaluated as statistically significant. Statistical analyses were performed using SPSS16.0 for Windows software (SPSS, Chicago, IL).


Characteristics of N-glycome profiling in IgD MM

Twenty patients with IgD MM were identified, and the patient characteristics are presented in Table 1.
Table 1

Baseline characteristics of patients with IgD MM, LCMM and healthy CTRs

M protein type



Healthy CTR

(κ 1, λ 19)

(κ 19, λ 22)

(n = 42)

Male (%)

12 (60.0%)

26 (63.4%)

25 (59.5%)


56.75 ± 9.51

58.17 ± 12.14

59.14 ± 5.90

ISS stage I

4 (20.0%)

11 (26.8%)


ISS stage II

5 (25.0%)

3 (7.3%)


ISS stage III

11 (55.0%)

27 (65.9%)


Durie Salmon stage IIIA

16 (80.0%)



Durie Salmon stage IIIB

4 (20.0%)




89.50 ± 20.61

100.28 ± 28.46

146.34 ± 9.42

Total protein

62.95 ± 8.83

60.88 ± 7.89

76.24 ± 3.87


36.33 ± 4.60

39.23 ± 5.51

47.17 ± 2.18

Serum FLC ratio

2.62 ± 1.74



Urine FLC ratio

204.47 ± 262.98



SPE positive (%)

13 (65.0%)

11 (26.8%)


IFE positive (%)

18 (90.0%)

23 (56.1%)


Bone lesions (%)

14 (70.0%)



Extramedullary infiltration (%)

3 (15.0%)



Note: Quantitative data are expressed as the means ± standard deviation; qualitative data are expressed as n (%);/represents no relevant data documented

Abbreviations: ISS international staging system, SPE serum protein electrophoresis, IFE immunofixation electrophoresis, FLC free light chain (including 15 serum samples and 16 urine samples in patients with IgD MM)

As mentioned above, 12 N-glycan peaks were detected in all the serum samples (Fig. 1). The corresponding structure of each N-glycan peak was previously determined by Liu et al. and Bunz SC et al. [2527]. The average abundance of the 12 N-glycan peaks in the IgD MM, LCMM and healthy CTR groups is shown in Table 2.
Fig. 1

Characteristic N-linked glycan profile from total serum proteins. Twelve peaks were confirmed in the IgD MM, LCMM and healthy control groups. The structures of the corresponding N-glycan peaks are presented

Table 2

Abundance of 12 N-glycan structures attached to serum proteins in IgD MM, LCMM patients and healthy CTRs


Healthy CTR





(n = 42)

(κ 1, λ 19)

(κ 19, λ 22)


7.79 ± 1.94

5.77 ± 2.04

6.93 ± 3.00




1.30 ± 0.45

1.06 ± 0.80

0.90 ± 0.54




6.32 ± 1.11

3.17 ± 1.09

3.44 ± 1.40




5.61 ± 1.22

3.53 ± 0.97

4.15 ± 0.84




38.76 ± 3.06

44.07 ± 6.20

47.49 ± 6.43




20.14 ± 2.54

18.50 ± 9.56

14.76 ± 5.63




6.21 ± 1.40

4.85 ± 3.37

2.52 ± 2.40




7.80 ± 1.96

9.84 ± 3.26

10.08 ± 3.51




2.68 ± 1.28

4.57 ± 3.14

5.04 ± 3.21




0.34 ± 0.13

0.42 ± 0.16

0.46 ± 0.23




1.69 ± 0.61

2.97 ± 0.95

3.01 ± 1.36




0.47 ± 0.24

1.25 ± 0.89

1.22 ± 0.73



Note: Quantitative data are expressed as the means ± standard deviation; P1: comparison between IgD MM patients and healthy CTR

P2: comparison between IgD MM and LCMM patients

Abbreviations: IgD MM IgD multiple myeloma, LCMM light chain multiple myeloma, CTR control subject, NS non-significant

The levels of three complex-type biantennary N-glycans, the agalactosylated NGA2F, α(1,6)-arm monogalactosylated NG1(6)A2F and α(1,3)-arm monogalactosylated NG1(3)A2F (identified as peaks 1, 3 and 4, respectively) were significantly lower in the IgD MM patients than in the CTRs. Moreover, the levels of bigalactosylated biantennary glycan NA2 (peak5), together with all the triantennary and tetra-antennary glycans NA3, NA3Fb, NA3F2, NA4 and NA4Fb (defined as peaks 8, 9, 10, 11 and 12, respectively), were significantly higher in the IgD MM patients than in the CTRs.

Next, we compared the IgD MM and LCMM groups because their serum N-glycomic profiles were similar to those of the CTRs. The 2 groups showed low levels of partial biantennary structures and high levels of NA2, triantennary and tetra-antennary glycan structures. The increase in multi-antennary peaks may affect the decreased concentration of IgG present in high abundance in the human circulation and the peaks represent predominantly biantennary complex-type structures. Notably, the significant decrease in NG1(3)A2F levels and prominent increase in NA2FB (peak7) levels were more evident in patients with IgD MM than in those with LCMM. In addition, none of the N-glycan peaks were significantly different between the newly diagnosed and treated IgD MM patients (Additional file 2: Table S2), and there were no differences between the kappa and lambda chain subjects with IgD MM because of the predominance of lambda chain (accounting for 95%).

N-glycan biomarkers in different stages of IgD MM

Next, we evaluated the association between the levels of serum N-glycomic structures and different tumour stages. For this purpose, 4 ISS stage I, 5 ISS stage II and 11 ISS stage III IgD MM patients were recruited; additionally, all the patients with IgD MM were diagnosed with Durie Salmon stage III (including 16 IIIA and 4 IIIB patients). NG1(3)A2F levels differed significantly between ISS stage I and ISS stage III patients (P = 0.011, Fig. 2a). Moreover, the level of NA3F2 was significantly higher in patients with Durie Salmon stage IIIB than in those with stage IIIA (P = 0.036, Fig. 2b). Therefore, the lower trend of the NG1(3)A2F level was related to a higher ISS stage, and a higher level of NA3F2 was associated with a greater probability of Durie Salom stage IIIA to IIIB.
Fig. 2

Comparison of the serum N-glycan structures according to different disease stage systems in IgD MM patients. a The tendency towards lower levels of NG1(3)A2F (peak4) was present in patients with a higher ISS stage, and levels of NG1(3)A2F were significantly different between ISS stage I and ISS stage III. b The levels of NA3F2 (peak10) were significantly higher in Durie Salmon stage IIIB than in stage IIIA

Association of the N-glycan biomarkers and laboratory parameters in IgD MM

Until now, SPE and IFE were the preferred methods of detection of monoclonal proteins in IgD MM patients. Therefore, we compared the levels of N-glycan peaks between the negative and positive groups. We found that, for SPE and IFE, the levels of NA2FB were significantly higher in the positive group compared with the negative group (P = 0.001 and P = 0.036, respectively, Fig. 3). Moreover, other laboratory parameters, namely, haemoglobulin (Hb), platelets (PLT), serum/urine light chain ratio, urea (BUN), creatinine (CREA), total protein (TP) and albumin (ALB) were collected. The decreased N-glycan peaks in the IgD MM patients presented a negative association with the serum or urine light chain ratios and a positive association with Hb, such as NGA2F versus the urine light chain ratio; NG1(6)A2F or NG1(3)A2F versus Hb and the serum/urine light chain ratio (Table 3). Additionally, increased N-glycan peaks showed a negative correlation with TP and ALB, e.g., NA2 or NA4 versus TP and NA3F2 versus ALB (Table 3).
Fig. 3

Comparison of the levels of NA2FB (peak7) between the SPE- and IFE-positive and -negative IgD MM patients. a Different levels of NA2FB were found between the SPE-positive and -negative groups. b Different levels of NA2FB were shown between the IFE-positive and -negative groups

Table 3

Comparison between N-glycan markers and laboratory parameters in IgD MM patients
















(n = 20)
















(n = 20)
















(n = 20)








SLC ratio








(n = 15)








ULC ratio








(n = 16)








Abbreviations: Hb haemoglobulin, TP total protein, ALB albumin, SLC serum light chain, ULC urine light chain

Using κ/λ ratio for IgD κ MM patients and λ/κ ratio for IgD λ MM patients

arepresents N-glycan biomarkers with a significant correlation with corresponding laboratory indexes

Performance of N-glycan biomarkers in the diagnosis and differential diagnosis of IgD MM

To further evaluate the potential clinical usefulness of these 9 N-glycan constructions as diagnostic serum markers, we employed ROC curve analysis to assess these N-glycan markers. As shown in Fig. 4, NG1(6)A2F and NG1(3)A2F presented the best diagnostic performance, with AUCs of 0.981 (95% CI 0.949–1.013) and 0.936 (95% CI 0.869–1.003). The optimal cut-off value for NG1(6)A2F was 4.819 (sensitivity 95.0%, specificity 95.2%, accuracy 95.1%), and that for NG1(3)A2F was 4.640 (sensitivity 95.0%, specificity 78.6%, accuracy 86.8%) (Table 4). In this study, 7 SPE negative and 2 IFE negative IgD MM patients could be diagnosed properly by N-glycan markers NG1(6)A2F and NG1(3)A2F (Additional file 3: Table S3).F.
Fig. 4

Diagnostic performance of N-glycan biomarkers in IgD MM. (a) and (b) The abundances of NG1(6)A2F (peak3) and NG1(3)A2F (peak4) were significantly decreased in patients with IgD MM than in CTRs. c ROC curves demonstrated the ability of serum NG1(6)A2F and NG1(3)A2F levels to diagnose IgD MM

Table 4

Cut-off value, sensitivity, specificity, PPV, NPV and accuracy of N-glycan biomarkers in the diagnosis and differential diagnosis of IgD MM

Cut off value

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

Accuracy (%)

NG1(6)A2F (IgD MM vs Control)







NG1(3)A2F (IgD MM vs Control)







NA2FB/NG1(3)A2F (IgD MM vs LCMM)







Abbreviations: PPV positive predictive value, NPV negative predictive value

Because most of the IgG MM and IgA MM cases can be identified by SPE and IFE and the N-glycomic profiles of serum proteins were quite similar between the IgD MM and LCMM patients (as described above), we intended to differentially diagnose IgD MM from LCMM only. The ratio of NA2FB/NG1(3)A2F (peak7/peak4) was selected as the differential diagnostic marker for NA2FB levels were significantly higher in the IgD MM group than in the LCMM group, while NG1(3)A2F levels were significantly lower in the former than in the latter. NA2FB/NG1(3)A2F showed comparably differential diagnostic performance with an AUC of 0.744 (95% CI 0.605–0.883, Fig. 5). The optimal cut-off value for NA2FB/NG1(3)A2F was 0.953 (sensitivity 95.3%, specificity 50.0%, accuracy 72.7%) (Table 4).
Fig. 5

The differential diagnostic performance of N-glycan biomarkers in IgD MM. a The abundance of NA2FB/NG1(3)A2F (peak 7/peak 4) was significantly increased in patients with IgD MM compared with those with LCMM. b The ROC curve demonstrated the ability of the serum NA2FB/NG1(3)A2F levels to differentially diagnose IgD MM from LCMM

In this study, one patient whose NA2FB/NG1(3)A2F level was 3.307 at the first-time diagnosis of LCMM was eventually confirmed with the subtype of IgD lambda 37 months later. Therefore, the increased level of NA2FB/NG1(3)A2F probably indicated the presence of IgD monoclonal protein, while IFE and SPE already showed a light chain-only or negative result.

High levels of NA2FB correlate with a poor prognosis in IgD MM

To determine the correlation between the abundance of N-glycan markers and clinical outcome, we analysed the prognostic significance of N-glycan markers using Kaplan-Meier analysis. The median follow-up of the entire IgD MM patient cohort was 31.5 months. The comparison was executed between the above- and below-median concentrations of each N-glycan peak. Finally, as shown in Fig. 6, the progression free survival (PFS) time of IgD MM patients with above-median levels of NA2FB was significantly shorter than that of patients with below-median levels of NA2FB (P = 0.008). Additionally, the subjects with NA2FB levels above the median level exhibited a shorter overall survival (OS) time, and those with NA2FB levels below the median level showed a relatively longer OS time (30.7 and 41.6 months, respectively), although the difference was not statistically significant.
Fig. 6

Survival curves for IgD MM using the Kaplan-Meier method and log-rank test. a Progression free survival (PFS) curves for patients with above median levels of NA2FB (red line, 10.9 months) and patients with below median levels of NA2FB (blue line, 27.0 months); (b) Overall survival (OS) curves for patients with above median levels of NA2FB (red line, 30.7 months) and patients with below median levels of NA2FB (blue line, 41.6 months)


Glycosylation is a major post-translational modification of proteins for cellular function. Nearly half of human serum proteins, including secretory and membrane-bound proteins, are suggested to exhibit various N-linked glycosylation patterns [28]. Many glycan structures of proteins can influence various aspects of the biological behaviours of tumour cells during carcinogenesis [2932]. Altered glycosylation patterns have long been recognized as hallmarks of cancer progression and metastasis [3335]. The sensitive detection of serum N-glycosylation changes and abnormalities using the DSA-FACE technique developed in this study serve as a unique foundation for the development of diagnostic and prognostic N-glycan biomarkers for IgD MM. We found that the levels of NGA2F (peak1), NG1(6)A2F (peak3) and NG1(3)A2F (peak4) were significantly lower in the IgD MM patients than in the CTRs. In addition, the levels of NA2 (peak5), NA3 (peak8), NA3Fb (peak9), NA3F2 (peak10), NA4 (peak11) and NA4Fb (peak12) were prominently higher in the IgD MM patients than in the CTRs. These structural varieties may occur because of the altered levels of glycosyltransferases, glycosidases, and sugar nucleotide donors [36]. The increase in all triantennary and tetra-antennary N-glycans, with the decrease in agalactosylated and monogalactosylated structures, may provide more binding sites (galactose) for terminal sialic acid and activate related enzymes. Glavey SV et al. demonstrated the high expression of sialyltransferase ST3GAL6 (β-galactoside α-2, 3-sialyltransferase) influences homing and survival in MM [37]. Until now, certain sialyltransferase inhibitors may become novel therapeutic strategies targeting related abnormal glycosylation reported to suppress the malignancy, invasion, and metastasis of tumours [3840].

We also identified a gradual downtrend of the NG1(3)A2F (peak4) levels from ISS stage I to ISS stage III in IgD MM patients. Significant differences occurred in the levels of NG1(3)A2F between the ISS stage I and ISS stage III groups. A significant increase was also found in the levels of NA3F2 (peak10) between Durie Salmon stage IIIB and IIIA patients. These serum N-glycomic changes indicate that the levels of NG1(3)A2F were strongly negatively correlated with ISS stage or IgD MM severity, and the levels of NA3F2 were positively correlated with renal insufficiency in patients with Durie Salmon stage III. Moreover, the levels of NGA2F, NG1(6)A2F or NG1(3)A2F were decreased more with the increased concentrations of the serum/urine light chain ratio and decreased levels of Hb. The levels of NA2, NA3F2 and NA4 were increased more with the decreased concentrations of TP or ALB. High levels of NA2FB were associated with SPE and IFE positivity. These results clearly demonstrated that the changes in some N-glycans are sensitive biomarkers for some typical syndromes in IgD MM, such as anaemia, abnormal secretion of monoclonal proteins and hypoproteinaemia.

As mentioned above, the main problem in diagnosing IgD MM is the uncertain appearance of an M spike in SPE, whether due to heavy chains or light chains. In this regard, Kuliszkiewicz-Janus M et al. reported an M spike in SPE only in 60% of IgD MM patients [20]. A similar observation was shown in this study with a 65% positive rate of SPE. The main reason is that IgD is a unique immunoglobulin with a serum concentration far below those of IgG, IgA, and IgM and has usually been ignored by routine tests. IgD accounts for 0.25% of the total serum immunoglobulins and has a half-life of 2.8 days [41]. The synthesis rate of IgD is at least 10 times lower than that of IgA, IgM, and IgG [42]. Arnaud P et al. [43] previously reported that only 31.5% of IgD was intravascular in patients with IgD MM. Therefore, the low concentration of IgD makes the detection result false-negative. All the patients with confirmed IgD MM in our study had Durie Salmon stage III. Some patients had been misdiagnosed with bone injury or had been diagnosed first with LCMM or non-secretory MM. Our study showed that the N-glycan biomarkers could overcome the limitation of measuring monoclonal IgD with conventional techniques (SPE or IFE). The sensitivity and specificity of NG1(6)A2F for the diagnosis of IgD MM were 95.0% and 95.2%, respectively, and the sensitivity and specificity of NG1(3)A2F were 95.0% and 78.6%, respectively. Both markers could avoid the false-negative SPE and IFE results in our study. Based on the diagnostic value of NG1(6)A2F in LCMM [19], we recommend NG1(3)A2F combined with NG1(6)A2F as diagnostic markers for IgD MM and NG1(3)A2F combined with NA2FB for LCMM. Additionally, the results of SPE and IFE, together with the quantitative determination of serum IgD and light chains using a nephelometer still need to be considered in the diagnosis.

Because of the similarity of the serum N-glycomic profile between IgD MM and LCMM, the differential diagnosis was focused on these two subtypes. The ratio of NA2FB/NG1(3)A2F was selected as the marker for the differential diagnosis with a sensitivity and specificity of 95.3% and 50.0%, respectively. Due to the presence of abnormal IgD monoclonal immunoglobulin in IgD MM, the increase in NA2FB and decrease in NG1(3)A2F may arise from the N-glycosylated characteristic of IgD. Arnold et al. [44] reported that 19% of N-glycans terminate in galactose residues, 50% of the glycans contain core fucosylation and 50% contain a bisecting GlcNAc at Asn-445 and Asn-496 of IgD. Therefore, whether the abnormal IgD leads to this specific change in IgD MM still needs further research in the future.

Moreover, the level of NA2FB was identified as an important prognostic factor in IgD MM. A higher level of NA2FB showed a prominent shorter PFS time than a lower level of NA2FB, but no statistical significance was found in OS between the higher and lower levels in the NA2FB group.


In summary, the characterization of the N-glycomic profile was, for the first time, explained in patients with IgD MM. The findings presented here indicated a considerable diagnostic, staging and prognostic potential of the N-glycan biomarkers in this rare subtype of MM. We still need to emphasize the importance of disclosing the relevant molecular mechanisms underlying the unique composition of the N-glycan signatures in IgD MM.





A proliferation-inducing ligand


8-aminonaphtalene-1,3,6-trisulphonic acid


Area under the curve






Healthy control subjects


Coefficient of variation


DNA sequencer-assisted fluorophore-assisted capillary electrophoresis


Epidermal growth factor




Hepatocyte growth factor


Immunofixation electrophoresis


Insulin-like growth factor


Insulin-like growth factor binding proteins


International Myeloma Working Group


International staging system


Light chain multiple myeloma


monoclonal gammopathy of undetermined significance


Multiple myeloma


Negative predictive value


Overall survival




Progression-free survival


Peptide N-glycosidase-F


Positive predictive value


Receiver Operating Characteristic


Standard deviation


Smoldering multiple myeloma


Serum protein electrophoresis


Total protein



We thank all the participants and case managers for their invaluable help with data collection.


The study was supported by the Natural Science Foundation of China (No, 81,101,639, 81,271,925, 81,301,877) and the General Program of Shanghai Health and Family Planning Commission (grants 201,540,089). Neither of them took any part in study design, data collection, analysis, interpretation of data or in writing the manuscript.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

JC and MF made substantial contributions to conception and design; acquisition of data; analysis and interpretation of data; drafted the manuscript. XC was involved in study design; collection of patient sample and data; revising the manuscript critically for important intellectual content. CY and JJ made substantial contributions to N-glycan profiling analysis and interpretation of data. CC and MW renewed the database to this project and was responsible for gathering information in the database; preforming statistical analysis and interpreting the results. XG and QS were major contributors in writing the manuscript and in performing the statistical analyses. CG was involved in study design; revising the manuscript critically for important intellectual content; gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript, and ensure that this is the case.

Ethics approval and consent to participate

The study protocol was approved by the Chinese Ethics Committee of Human Resources at the Second Military Medical University. Written informed consent was obtained from all study participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Laboratory Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
Department of Laboratory Medicine, Shanghai Jingan District Zhabei Central Hospital, Shanghai, China
Department of Hematology, Shanghai Jingan District Zhabei Central Hospital, Shanghai, China


  1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc. 2003;78(1):21–33.View ArticleGoogle Scholar
  2. Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398–404.View ArticlePubMedGoogle Scholar
  3. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med. 1975;135(1):87–93.View ArticlePubMedGoogle Scholar
  4. Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau JL, Morgan G, de Witte T, Niederwieser D, Gahrton G. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010;95(12):2126–33.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Jenkins N, Curling E. Glycosylation of recombinant proteins: problems and prospects. Enzym Microb Technol. 1994;16(5):354–64.View ArticleGoogle Scholar
  6. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10(4):429–34.View ArticlePubMedGoogle Scholar
  7. An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li B, Lam KS, Leiserowitz GS, Lebrilla CB. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5(7):1626–35.View ArticlePubMedGoogle Scholar
  8. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011;21(2):195–205.View ArticlePubMedGoogle Scholar
  9. Arnold JN, Saldova R, Galligan MC, Murphy TB, Mimura-Kimura Y, Telford JE, Godwin AK, Rudd PM. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res. 2011;10(4):1755–64.View ArticlePubMedGoogle Scholar
  10. Mittermayr S, Lê GN, Clarke C, Millán Martín S, Larkin AM, O'Gorman P, Bones J. Polyclonal immunoglobulin G N-glycosylation in the pathogenesis of plasma cell disorders. J Proteome Res. 2017;16(2):748–62.View ArticlePubMedGoogle Scholar
  11. Kovacs Z, Simon A, Szabo Z, Nagy Z, Varoczy L, Pal I, Csanky E, Guttman A. Capillary electrophoresis analysis of N-glycosylation changes of serum paraproteins in multiple myeloma. Electrophoresis. 2017;38(17):2115–23.View ArticlePubMedGoogle Scholar
  12. Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment. Nat Protoc. 2006;1(1):397–405.View ArticlePubMedGoogle Scholar
  13. Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF, Klein BAPRIL. TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol. 2009;83(2):119–29.View ArticlePubMedGoogle Scholar
  14. Mahtouk K, Hose D, Rème T, De Vos J, Jourdan M, Moreaux J, Fiol G, Raab M, Jourdan E, Grau V, Moos M, Goldschmidt H, Baudard M, Rossi JF, Cremer FW, Klein B. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene. 2005;24(21):3512–24.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Mahtouk K, Cremer FW, Rème T, Jourdan M, Baudard M, Moreaux J, Requirand G, Fiol G, De Vos J, Moos M, Quittet P, Goldschmidt H, Rossi JF, Hose D, Klein B. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene. 2006;25(54):7180–91.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113(19):4614–26.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes met signaling in multiple myeloma. Blood. 2002;99(4):1405–10.View ArticlePubMedGoogle Scholar
  18. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007;110(6):2041–2048.Google Scholar
  19. Chen J, Fang M, Zhao YP, Yi CH, Ji J, Cheng C, Wang MM, Gu X, Sun QS, Chen XL, Gao CF. Serum N-Glycans: a new diagnostic biomarker for light chain multiple myeloma. PLoS One. 2015;10(6):e0127022.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Kuliszkiewicz-Janus M, Zimny A, Sokolska V, Saşiadek M, Kuliczkowski K, Immunoglobulin D. Myeloma--problems with diagnosing and staging (own experience and literature review). Leuk Lymphoma. 2005;46(7):1029–37.View ArticlePubMedGoogle Scholar
  21. Pandey S, Kyle RA. Unusual myelomas: a review of IgD and IgE variants. Oncology (Williston Park). 2013;27(8):798–803.Google Scholar
  22. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 2003;121(5):749–57.View ArticleGoogle Scholar
  23. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.View ArticlePubMedGoogle Scholar
  24. Fang M, Zhao YP, Zhou FG, LG L, Qi P, Wang H, Zhou K, Sun SH, Chen CY, Gao CF. N-Glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2010;127(1):148–59.View ArticlePubMedGoogle Scholar
  25. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen C. N-Glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007;46(5):1426–35.View ArticlePubMedGoogle Scholar
  26. Bunz SC, Rapp E, Neusüss C. Capillary electrophoresis/mass spectrometry of APTS-labeled glycans for the identification of unknown glycan species in capillary electrophoresis/laser-induced fluorescence systems. Anal Chem. 2013;85(21):10218–24.View ArticlePubMedGoogle Scholar
  27. Testa R, Vanhooren V, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, Genovese S, Spazzafumo L, Borelli V, Bacalini MG, Salvioli S, Garagnani P, Dewaele S, Libert C, Franceschi C. N-Glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One. 2015;10(3):e0119983.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta. 1999;1473(1):4–8.View ArticlePubMedGoogle Scholar
  29. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res. 1989;52:257–331.View ArticlePubMedGoogle Scholar
  30. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004;95(5):377–84.View ArticlePubMedGoogle Scholar
  31. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, Dennis JW. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004;306(5693):120–4.View ArticlePubMedGoogle Scholar
  32. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW. Complex N-Glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007;129(1):123–34.View ArticlePubMedGoogle Scholar
  33. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1999;1473(1):21–34.View ArticlePubMedGoogle Scholar
  34. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM. Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. J Proteome Res. 2014;13(5):2314–27.View ArticlePubMedGoogle Scholar
  35. Zhao YP, XY X, Fang M, Wang H, You Q, Yi CH, Ji J, Gu X, Zhou PT, Cheng C, Gao CF. Decreased core-fucosylation contributes to malignancy in gastric cancer. PLoS One. 2014;9(4):e94536.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Yarema KJ, Bertozzi CR. Characterizing glycosylation pathways. Genome Biol. 2001;2(5):REVIEWS0004.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, Roccaro AM, Ghobrial IM, O'Dwyer ME. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood. 2014;124(11):1765–76.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Li W, Niu Y, Xiong DC, Cao X, Ye XS. Highly substituted Cyclopentane-CMP conjugates as potent Sialyltransferase inhibitors. J Med Chem. 2015;58(20):7972–90.View ArticlePubMedGoogle Scholar
  39. Chen JY, Tang YA, Huang SM, Juan HF, LW W, Sun YC, Wang SC, KW W, Balraj G, Chang TT, Li WS, Cheng HC, Wang YCA. Novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 2011;71(2):473–83.View ArticlePubMedGoogle Scholar
  40. Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, Dell A, Haslam SM, Paulson JC. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol. 2012;8(7):661–8.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Rogentine GN Jr, Rowe DS, Bradley J, Waldmann TA, Fahey JL. Metabolism of human immunoglobulin D (IgD). J Clin Invest 1966;45(9):1467–1478.Google Scholar
  42. Vladutiu AO, Immunoglobulin D. Properties, measurement, and clinical relevance. Clin Diagn Lab Immunol. 2000;7(2):131–40.PubMedPubMed CentralGoogle Scholar
  43. Arnaud P, Dechavanne M, Creyssel R. Metabolism of human monoclonal immunoglobulin D. A study in two patients with monoclonal IgD gammapathy. Biomedicine. 1974;21(2):77–81.PubMedGoogle Scholar
  44. Arnold JN, Radcliffe CM, Wormald MR, Royle L, Harvey DJ, Crispin M, Dwek RA, Sim RB, Rudd PM. The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin. J Immunol. 2004;173(11):6831–40.View ArticlePubMedGoogle Scholar


© The Author(s). 2017